| Model Number |
6900P |
| Medical Device Problem Codes |
Calcified (1077); Insufficient Device Problem Information (3190)
|
| Health Effect - Clinical Code |
Insufficient Information (4580)
|
| Date of Event |
07/02/2024
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
| |
|
Event or Problem Description
|
|
It was learned through implant patient registry that a patient with a 27mm 6900p mitral valve was explanted after an implant duration of 6 years, 7 months due to unknown reasons.The explanted valve was replaced with a 27mm 11400m mitris resilia mitral valve.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
|
| |
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: updated sections : b7, g3, g6, h2 , h6 (type of investigation) corrected sections :h6( component code, device code, investigation finding, investigation conclusions).Calcific degeneration is a common cause of bioprosthetic heart valve failures.Many factors contribute to the onset and propagation of calcification.These include patient factors (age, disease state, pharmacological intervention, etc.), mechanical stress related to the valve's hemodynamic performance, and glutaraldehyde fixation of tissue.Of these, the fixation process is a relatively minor contributor to calcification for edwards' tissue valves due to anti-calcification treatments during manufacturing.Though numerous studies have been conducted on preventive calcification strategies in bioprosthetic heart valves, the causes of calcification are not fully understood and there are still no mechanisms or medical therapies which fully prevent bioprostheses from calcifying.Calcification is most commonly related to patient factors and is not usually an indication of a device malfunction related to a manufacturing deficiency.An engineering evaluation is not required because there is no allegation of a malfunction which could be related to a manufacturing non-conformance and/or one was not suspected or confirmed through investigation; no labeling non-conformance/deficiency; no use-related issue with a hazardous situation; no device-related infection; and no evidence of a product failure with regard to design, reliability, or use error.A definitive root cause cannot be conclusively determined; however, patient factors likely caused or contributed.The device history record (dhr) review was completed, and this device passed all manufacturing and sterilization inspections prior to release for distribution.There were no issues identified that would have impacted this event.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
| |
|
Event or Problem Description
|
|
It was learned from implant patient registry and investigation that a patient with a 27mm 6900p in the mitral position underwent a valve explant after an implant duration of six (6) years, seven (7) months due to extensive calcifications.The explanted valve was replaced with a 27mm 11400m valve.Per pathology reports, calcifications have been detected on the cusps of the bioprosthetic valve, and areas of vegetation have also been identified.This 79-year-old male patient.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
|
| |
|
Search Alerts/Recalls
|
|